From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Journal of Cancer Policy

Health-Related Quality of Life Data Collected in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Clinical Trials

Blood

Response to SARS-CoV-2 Vaccination in Patients After Hematopoietic Cell Transplantation and CAR T-Cell Therapy

Nature Reviews Clinical Oncology

Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion

Expert Opinion on Investigational Drugs

CAR-T Cell Therapy for Triple-Negative Breast Cancer and Other Solid Tumors: Preclinical and Clinical Progress

Nature Medicine

Gut Microbiome Correlates of Response and Toxicity Following Anti-CD19 CAR T Cell Therapy

Transplantation and Cellular Therapy

Change in Neurocognitive Performance Among Patients With Non-Hodgkin’s Lymphoma in the First Year After CAR T-Cell Therapy

Blood Cancer Discovery

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States

JAMA Oncology

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Frontiers in Oncology

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Transplantation and Cellular Therapy Journal

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following CAR-T Cell Therapy: A Systematic Review

Journal of Oncology Pharmacy Practice

The Pharmacist’s Role in Chimeric Antigen Receptor T Cell Therapy

Biology of Blood and Marrow Transplantation

Implementation of an Oncology Nurse Practitioner Fellowship Program Focused on Adult Stem Transplant and Cellular Therapy Training

Molecular Cancer

Next Generation Chimeric Antigen Receptor T Cells: Safety Strategies to Overcome Toxicity

The ASCO Post

CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas

Journal for ImmunoTherapy of Cancer

Perspectives on Outpatient Administration of CAR-T Cell Therapy in Aggressive B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Radiology

Imaging-Based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy

Nature

Decade-Long Leukaemia Remissions With Persistence of CD4+ CAR T Cells

Blood Reviews

Current State and Next-Generation CAR-T Cells in Multiple Myeloma

The ASCO Post

POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

International Journal of Molecular Sciences

CAR T-Cell Therapy in Hematological Malignancies

BioDrugs

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Stem Cell Research & Therapy

Novel CAR T Therapy is a Ray of Hope in the Treatment of Seriously Ill AML Patients

Blood Cancer Journal

CAR-T Cell Therapy: Current Limitations and Potential Strategies

2021 ASH Annual Meeting & Exposition

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Journal of Geriatric Oncology

Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years

Nature Reviews Clinical Oncology

Immunogenicity of CAR T Cells in Cancer Therapy

JAMA Oncology

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

2021 ASH Annual Meeting & Exposition

Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood Adv

Optimal Fludarabine Lymphodepletion is Associated With Improved Outcomes Following CAR T-Cell Therapy

Chronic Dis Transl Med

Major Advances in the Treatment of Multiple Myeloma in American Society of Hematology Annual Meeting 2020

Clin Lymphoma Myeloma Leuk

CAR-T in B-Cell Lymphomas: The Past, Present, and Future

Oncol Ther

Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated With CAR T-Cell Therapy: A Qualitative Study

Memo

CAR T Cell Therapy in Solid Tumors: A Short Review

Nature Communications

Biallelic Loss of BCMA as a Resistance Mechanism to CAR T Cell Therapy in a Patient With Multiple Myeloma

Annals of Clinical and Translational Neurology

Brain Dysfunction in COVID-19 and CAR-T Therapy: Cytokine Storm-Associated Encephalopathy

Frontiers in Immunology

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia

Seminars in Oncology Nursing

Chimeric Antigen Receptor T-Cell Emergencies: Inpatient Administration, Assessment, and Management

Journal of the American College of Cardiology

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

The Cancer Journal

Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight

Journal of Clinical Oncology

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Infection

Recommendations for Screening, Monitoring, Prevention, and Prophylaxis of Infections in Adult and Pediatric Patients Receiving CAR T-Cell Therapy: A Position Paper

Nature Reviews Cancer

Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells

Blood Advances

Infectious Complications in Relapsed Refractory Multiple Myeloma Patients After BCMA CAR T-Cell Therapy

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

Blood Advances

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

Expert Review of Anti-Infective Therapy

CAR-T Cell Therapy and Infection: A Review

Biology of Blood and Marrow Transplantation

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Journal of Blood Medicine

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Nature Medicine

CAR T Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial

Blood Reviews

Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management

The ASCO Post

Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma

Hemasphere

In the Eye of the Storm: Immune-Mediated Toxicities Associated With CAR-T Cell Therapy

Nature Medicine

Antigen-Independent Activation Enhances The Efficacy of 4-1BB-Costimulated CD22 CAR T Cells

Journal for ImmunoTherapy of Cancer

Thrombopoietin Receptor Agonists for Acquired Thrombocytopenia Following Anti-CD19 CAR-T-Cell Therapy: A Case Report

Clinical Infectious Diseases

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Frontiers in Oncology

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

The Lancet

KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study

Clinical Cancer Research

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Journal of Cancer

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Nature Reviews Clinical Oncology

Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Journal of the Advanced Practitioner in Oncology

CAR T-Cell Therapy: Adverse Events and Management

Journal of Clinical Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

The ASCO Post

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Fast Facts #12: BCMA Targets